The ongoing conflicts between Ukraine and Russia, as well as Israel and Palestine, have sent ripples across various ...

If left unchecked, the power of PBMs and their complex relationships within the American healthcare system could lead to higher drug costs and diminished returns.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic ...

The future of the life sciences industry hinges on AI and automation, driving innovation in drug discovery and addressing ...

The Office of Insurance Regulation is demanding the unusual trove of data from pharmacy benefit managers — health care ...

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the Association of the British Pharmaceutical Industry (ABPI). As one of the ...

Alexander Malyshev and Sarah Ganley of Carter Ledyard & Milburn LLP discuss opposition efforts to legalization of cannabis ...

For decades, the United States has led the world in pharmaceutical innovation -- developing drugs that combat cancer, heart ...

The massive pharmacy benefit manager plans to stop requiring coverage authorizations for roughly 80 drugs used to treat ...

While consumer use soars, mom and pop businesses are struggling, a shutdown will be be another blow to the marijuana industry ...